Previous close | 1.2600 |
Open | 1.2400 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.2400 - 1.2800 |
52-week range | 0.6800 - 2.5700 |
Volume | |
Avg. volume | 110,245 |
Market cap | 35.892M |
Beta (5Y monthly) | -0.15 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2300 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.30 |
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
GAINESVILLE, Fla., March 18, 2024--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.
GAINESVILLE, Fla., March 14, 2024--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,925,659 titled, "Methods for Treating Alzheimer’s Disease," with claims that cover the use of Trappsol® Cyclo™ for th